Should latent tuberculosis infection be treated in a patient with a positive tuberculin skin test (purified protein derivative)?

Treatment of Latent TB in Positive PPD Test

Yes, you should treat latent tuberculosis infection (LTBI) in patients with a positive PPD test, but treatment is not indicated for all positive tests—it depends on the patient's risk profile and the specific cut-point used to define positivity. 1

Risk-Stratified Approach to Positive PPD

The decision to treat LTBI follows a targeted testing strategy where three different cut-points define a positive test based on the patient's risk level 1:

≥5 mm induration is positive in:

• HIV-infected persons
• Recent close contacts of infectious TB cases
• Persons with chest X-ray findings consistent with prior TB
• Patients on immunosuppressive therapy (organ transplant recipients, chronic corticosteroids, TNF-alpha inhibitors)

≥10 mm induration is positive in:

• Recent immigrants (within 5 years) from high-prevalence countries
• Injection drug users
• Healthcare workers and mycobacteriology laboratory personnel
• Residents/employees of high-risk congregate settings (prisons, nursing homes, homeless shelters)
• Persons with medical conditions increasing TB risk: silicosis, diabetes mellitus, chronic renal failure, leukemia/lymphoma, head/neck/lung cancer, >10% weight loss, gastrectomy, jejunoileal bypass
• Children <4 years old or those exposed to high-risk adults

≥15 mm induration is positive in:

• Low-risk persons (though testing is generally not indicated in this group)

Treatment Recommendations

Treatment of LTBI reduces active TB risk by 50-75% and is most effective in tuberculin-positive individuals 1. The benefit is particularly pronounced in those with positive skin tests (RR 0.38) compared to negative tests (RR 0.89) 2.

Key Treatment Principles:

Isoniazid (INH) monotherapy remains the standard regimen:

• 9 months of daily INH (300 mg/day) is the optimal duration 3
• 6-month regimens are acceptable but slightly less effective
• 12 months recommended for HIV-infected patients and those with radiographic evidence of old TB 4

Age considerations have evolved:

• High-risk persons should receive treatment irrespective of age 1
• The historical age 35 cut-off for low-risk persons was based on hepatotoxicity concerns, but routine monitoring has substantially reduced severe complications 1

Critical Pre-Treatment Steps

Before initiating LTBI treatment, you must:

1. Exclude active TB disease through:

   • Symptom inquiry (cough, fever, night sweats, weight loss, hemoptysis)
   • Chest radiography 5, 3
   • Sputum testing if radiographic abnormalities suggest old TB 3

2. Assess for contraindications:

   • Active hepatic disease
   • Previous INH-related hepatotoxicity
   • Pregnancy (relative contraindication—weigh risks/benefits)

Monitoring During Treatment

Routine laboratory monitoring is NOT required for all patients but is indicated for 1:

• Persons with abnormal baseline liver function tests
• Those at risk for hepatic disease (alcohol use, viral hepatitis, concurrent hepatotoxic medications)
• Age >35 years
• Pregnant/postpartum women

Withhold INH if:

• Transaminases >3× upper limit of normal WITH symptoms
• Transaminases >5× upper limit of normal WITHOUT symptoms 6, 1

Common Pitfalls to Avoid

1. Don't test low-risk populations—testing should only be performed when you intend to treat if positive, as false positives are common in low-prevalence groups 1

2. Don't assume all positive PPDs need treatment—the cut-point for positivity varies by risk group, and a 10 mm reaction in a low-risk person may not warrant treatment

3. Don't forget BCG vaccination history—while BCG can cause false-positive PPD results, this should not prevent treatment in high-risk individuals, as the protective effect of BCG wanes over time and doesn't reliably cause reactions >10 mm years after vaccination

4. Don't skip active TB exclusion—treating active TB with single-agent INH will lead to drug resistance

Alternative Regimens

While the guidelines focus primarily on INH, rifampin-based regimens (3-4 months) show equivalent efficacy but higher discontinuation rates due to adverse effects 2. These are reserved for INH-intolerant patients or contacts of INH-resistant cases.

The evidence strongly supports that identification and treatment of LTBI in high-risk populations is essential for TB control, as most active TB cases in low-incidence countries arise from reactivation of latent infection 1.